Literature DB >> 27019747

A review on prescribing patterns of antihypertensive drugs.

Noah Jarari1, Narasinga Rao2, Jagannadha Rao Peela3, Khaled A Ellafi4, Srikumar Shakila3, Abdul R Said3, Nagaraja Kumari Nelapalli5, Yupa Min6, Kin Darli Tun7, Syed Ibrahim Jamallulail8, Avinash Kousik Rawal9, Ranjani Ramanujam10, Ramesh Naidu Yedla11, Dhilip Kumar Kandregula12, Anuradha Argi13, Laxmi Teja Peela14.   

Abstract

Hypertension continues to be an important public health concern because of its associated morbidity, mortality and economic impact on the society. It is a significant risk factor for cardiovascular, cerebrovascular and renal complications. It has been estimated that by 2025, 1.56 billion individuals will have hypertension. The increasing prevalence of hypertension and the continually increasing expense of its treatment influence the prescribing patterns among physicians and compliance to the treatment by the patients. A number of national and international guidelines for the management of hypertension have been published. Since many years ago, diuretics were considered as the first-line drugs for treatment of hypertension therapy; however, the recent guidelines by the Joint National Commission (JNC8 guidelines) recommend both calcium channel blockers as well as angiotensin-converting enzyme inhibitors as first-line drugs, in addition to diuretics. Antihypertensive drug combinations are generally used for effective long-term management and to treat comorbid conditions. This review focuses on the antihypertensive medication utilization, their cost factors, adherence to treatment by patients, and physicians' adherence to guidelines in prescribing medications in different settings including Indian scenario. The antihypertensive medication prescribing pattern studies help in monitoring, evaluation and necessary modifications to the prescribing habits to achieve rational and cost-effective treatment. Additionally, periodic updating of recommended guidelines and innovative drug formulations, and prescription monitoring studies help in rational use of antihypertensive drugs, which can be tailored to suit the patients' requirements, including those in the developing countries.

Entities:  

Year:  2016        PMID: 27019747      PMCID: PMC4808570          DOI: 10.1186/s40885-016-0042-0

Source DB:  PubMed          Journal:  Clin Hypertens        ISSN: 2056-5909


Background

Hypertension is the most common modifiable risk factor for cardiovascular diseases (CVD), stroke and renal failure [1]. It is the second leading cause of chronic kidney disease (CKD). It is estimated that more than one billion adults are hypertensive worldwide and this figure is projected to increase to 1.56 billion by the year 2025, which is an increase of 60 % from 2000. Cardiovascular diseases and Hypertension are accounting for loss of 4 % gross domestic product for low and middle income countries annually which is amounting 500 billion USD [2]. Clinical evidence suggests that lowering blood pressure (BP) with antihypertensive drugs reduces the risk of myocardial infarction, stroke, heart failure, revascularization procedures and end-stage renal diseases in hypertensive patients [3]. The increasing prevalence of hypertension has been attributed to population growth, ageing and behavioral risk factors, such as unhealthy diet, excess use of alcohol, sedentary lifestyle, obesity, and exposure to persistent stress. A whopping 9.4 million deaths occur worldwide every year because of hypertension [4], with it being responsible for about 50 % of mortality due to heart disease and stroke [5]. Epidemiological studies demonstrated that prevalence of hypertension is increasing rapidly in India, varying from 4 to 15 % in urban and 2-8 % in rural population [6, 7]. Several guidelines have been developed worldwide for the management of hypertension, and these serve as reference standards for clinical practitioners. However, many clinicians practice their own prescribing pattern in treating hypertensive patients according to their clinical experience. Primary care physicians need to be empowered in appropriate and evidence-based management of hypertension. A review of these prescribing patterns and guideline-based use of antihypertensive medications can give better insights into the concept of personalised, yet cost-effective pharmacological management of hypertension.

Hypertension pharmacotherapy and guidelines

Antihypertensive drugs are prescribed mainly to reduce the morbidity and mortality caused by hypertension and its complications. Many a time, patients require more than one drug for effective control of hypertension. Various classes of antihypertensive drugs like diuretics, inhibitors of the renin-angiotensin system, calcium channel blockers (CCB) and beta blockers (BB) have been shown to reduce complications of hypertension and may be used for initial drugtherapy [8]. Since the need to improve the control of hypertension is well acknowledged, several guidelines on its classification and management have been developed. Some of the bodies which have developed guidelines are American Society of Hypertension/ International Society of hypertension (ASH/ISH), Joint National Committee (JNC) on Detection, Evaluation, and Treatment of High Blood Pressure, European Society of Hypertension (ESH)/European Society of Cardiology (ESC), National Institute for Health and Care Excellence (NICE) and Japanese Society of Hypertension. The JNC 8 guidelines published in 2014 are the most recent guidelines for the management of hypertension in different clinical settings. These guidelines were developed based on a systematic review of literature to help clinicians, especially the primary care physicians [3]. Despite these guidelines, and also evidence showing that hypertension is a major public health concern, many clinicians fail to assess BP routinely, and in those with a diagnosis of hypertension, do not start treatment or titrate the dosage of the drugs effectively [9]. The available guidelines recommend different goal BP levels and drug treatment options according to patients’ individual clinical need (see Table 1).
Table 1

Guideline comparisons of goal BP and initial drug therapy for adults with hypertension

GuidelinePopulationGoal BP, mmHgInitial drug treatment options
JNC 8: 2014 Hypertension Guideline [3]General ≥60 y<150/90Nonblack: thiazide-type diuretic, ACEI, ARB, or CCB; black: thiazide-type diuretic or CCB
General <60 y<140/90
Diabetes<140/90
CKD<140/90ACEI or ARB
ESH/ESC 2013 [42]General nonelderly<140/90Diuretic, BB, CCB, ACEI, or ARB
General elderly <80 y<150/90
General ≥80 y<150/90
Diabetes<140/85ACEI or ARB
CKD no proteinuria<140/90
CKD + proteinuria<130/90
Canadian Hypertension Education Program (CHEP) 2014 [43]General <80 y<140/90Thiazide, BB (age <60y), ACEI (nonblack), or ARB
General ≥80 y<150/90
Diabetes<130/80ACEI or ARB with additional CVD risk ACEI, ARB, thiazide, or dihydropyridine CCB without additional CVD risk
CKD<140/90ACEI or ARB
American Diabetes Association (ADA) 2013 [44]Diabetes<140/80ACEI or ARB
Kidney Disease: Improving Global Outcome (KDIGO) 2012 [45]CKD, no proteinuria≤140/90ACEI or ARB
CKD + proteinuria≤130/80
NICE 2011 [46]General <80 y<140/90<55 y: ACEI or ARB
General ≥80 y<150/90≥55 y or black: CCB
International Society for Hypertension in Blacks (ISHIB) 2010 [47]Black, lower risk<135/85Diuretic or CCB
Target organ damage or CVD risk<130/80
Korean Society of Hypertension Guidelines for the Management of Hypertension 2013 [48]Elderly (>65 years)<140/90ACEIs, CCBs and diuretics; BBs should be limited to special scenarios
Diabetes<140/85
Stroke, CAD and CKD140/90Combination therapy of ARBs, CCBs and diuretics
Guideline comparisons of goal BP and initial drug therapy for adults with hypertension Studies have shown that the application of guidelines to clinical practice improve the treatment outcomes. According to a retrospective study by Jackson et al. on 19,258 patients, applying JNC-7 guidelines to practice helped in achieving better BP control. Blood pressure control in the before-JNC 7 cohort was 40.8 % vs. 49.3 % in the after-JNC 7 cohort (p < 0.0001) [10]. In another older study conducted to assess whether the publication of JNC 6 (1997) and WHO/ISH (1999) guidelines, and the development of new drugs improved BP control, follow-up of 150 patients from 1991 to 2001 showed that BP control increased from 31 % initially, to 43 % in 1996 and finally to 57 % in 2001. Both younger and older patients showed similar improvement during these 10 years. The authors concluded that improved BP control was because of increased use of ACEIs and CCBs, lifestyle modifications and improved awareness about the disease condition and the need for effective management [11]. Jeschke et al. demonstrated that antihypertensive therapy prescribed by physicians specialized in complementary and alternative medicine (CAM) in Germany complied with the German Hypertension Society guidelines. Most patients were treated with conventional antihypertensives like BBs and ACEIs. A thiazide diuretic with ACEI was the most frequent combination prescribed [12].

Evaluating prescribing pattern of antihypertensive drugs

There have been several studies evaluating the prescribing pattern of antihypertensive drugs worldwide. Over the past 20 years, there has been a consistent increase in the use of ACEIs, ARBs and CCBs and many robustly conducted clinical studies have showed no consistent differences in antihypertensive efficacy, side effects and quality of life within these drug classes [13]. This has been supported by a retrospective time series data from 2007 to 2012 noted that the consumption of antihypertensive drugs in China nearly doubled [14]. The most frequently prescribed antihypertensive drug classes were CCBs and ARBs, with prescriptions of the latter increasing most rapidly [14]. Liu and Wang demonstrated that in 6,536 newly-diagnosed cases of uncomplicated hypertension, CCBs and BBs were the most prescribed antihypertensive medications. Surprisingly, the prescription rate of thiazide diuretics which are the least expensive, and well-known first-line antihypertensive therapy was low (8.3 % monotherapy and 19.9 % overall) [15]. Joseph et al. used Phadke’s criterion for assessment of appropriateness of prescribing. They observed that most patients were being treated with two or more drugs and CCBs were most frequently prescribed antihypertensive medicines. Similar to other studies, 67.92 % of the patients were prescribed more than one drug, with the most commonly used combination being CCB + BB + alpha-blocker (7.55 %). Based on Phadke’s evaluation criteria, 87.27 % of prescriptions were found rational [16].. In another drug utilization study, 645 prescriptions were analyzed. A total of 697 antihypertensive drugs prescribed, of which 33.57 % were ARBs, 16.79 % ACEIs, 13.63 % were BBs and 11.91 % CCBs. About 32 % of the antihypertensives prescribed were from the essential medicine list [17]. In a National Health and Nutrition Examination Survey conducted on subjects aged ≥18 years, it was observed that combination therapy regimens helped to achieve BP goals, with single-pill fixed dose combination (FDC) and multiple-pill combinations being associated with a 55 % and 26 % increased likelihood of BP control, respectively when compared to monotherapy. A significant increase in the use of multiple antihypertensive agents from 36.8 % to 47.7 % (p < 0.01), with an increased use of thiazide diuretics, BBs, ACEIs, and ARBs by 23 %, 57 %, 31 %, and 100 %, respectively was observed [18]. Al-Drabah et al. observed that majority of subjects in their study were prescribed monotherapy, followed by two drugs. A few others required three of more drugs. While ACEIs were the most commonly prescribed monotherapy, diuretics were the most commonly prescribed drugs in combination therapy. The researchers further observed that target BP control was not achieved in most patients which imply that monotherapy may not be sufficient for achieving adequate BP control in majority of the patients [19]. The notable findings of various studies have been presented in Table 2. As per our knowledge, there is no recent data on international variation in prescribing antihypertensive drugs, which can help clinicians to keep them updated with the recent trends.
Table 2

Findings from different studies conducted to evaluate prescribing pattern of antihypertensive drugs

Author nameNo. subjects involvedMono-/combination therapy prescribedAntihypertensive drug classObservation/Remarks
Caceres et al. [13]100 % of the Extremadura populationMonotherapyARBs, ACEIsUse of ARBs increased over ACEIs
Xu et al. [14]59 hospitals’ databasesMonotherapyCCBs, ARBs, ACEIs, BBs, and diureticsThe top-prescribed antihypertensive drug classes were CCBs and ARBs
Liu and Wang [15]6,536Mono and combinationCCBs (17.7 %), CCBs + beta-blockers (7.7 %)CCBs and BBs were the most prescribed antihypertensives
Joseph et al. [16]165Two or moreCCB87.27 % prescriptions were found rational
Beg et al. [17]645Two or moreARB225 antihypertensives were from essential medicines list
Gu et al. [18]9320MultipleARBWith Single pill combination 55 % likelihood of BP control
Al-Drabah et al. [19]416Mono (192)ACEIsMost patients did not achieve target BP
Findings from different studies conducted to evaluate prescribing pattern of antihypertensive drugs

Antihypertensive drug utilization and adherence

Antihypertensive medication utilization, adherence to treatment by patients, and physicians’ adherence to guidelines in prescribing medications have been studied in different settings. Many of them have noted full, partial or no-adherence in some studies. Studies suggest that formulators of guidelines should evolve treatment protocols which needs less frequent monitoring by physician, so as to suit developing countries patients. Globally, all guidelines address that guidelines are just to guide but physicians need to follow a patient-centric approach. Treatment strategies for developing countries, where access to health care system is less compared to developed countries, need to be simple, economic and forced time bound titration by the primary care physician and not by the specialist or the tertiary care physician, in order to reach maximum number of patients. A study conducted in India pointed to a common trend that the study patients were on multiple therapies with at least two antihypertensives. This pattern is recommended by guidelines, which state that small doses of different classes of antihypertensive drug are more beneficial than a high dose of one [20]. In a recent study, it has been noted that in India, the antihypertensive utilization pattern is in accordance with the international guidelines for treatment of hypertension. There is considerable use of different antihypertensive drug combinations and such practice has a positive impact on the overall BP control [21]. In a meta-analysis, Murphy et al. noted that no consistent differences were observed in the rates of utilization or adherence to drugs for CVDs or diabetes in subjects living in urban and rural settings [22]. Odili et al. studied the role of physicians in the overall management of hypertension and their adherence to JNC 7, WHO/ISH and ESH guidelines. They concluded that physicians in this study fairly complied with hypertension management guidelines. However, they did not appear to recommend lifestyle modification to their patients [23]. On the contrary, a study conducted in Malaysia, observed that doctors poorly adhered to Malaysian Clinical Practice Guideline (CPG) in hypertensive patients with diabetes and left ventricular hypertrophy. A better hypertension control was seen with ACEIs and guidelines-adherent therapy [24]. In another study by Abdulameer et al., 85.30 % of the prescriptions were in accordance to guidelines [25]. It was observed that the treatment approach for cardiac complicated hypertension followed JNC 7 guidelines, except the lack of add-on therapy practice (ARBs, aldosterone antagonist). The prescribing practice was found in compliance with the Eritrean National treatment guideline 2003 [26]. In a multicenter study, it was noted that even though physicians self-reported that they were aware of and implement hypertension guidelines in daily practice, a significantly lower agreement rate between physicians’ practice and European guidelines was detected. It was also found that more than one-fourth of high risk hypertensive patients remained untreated, half of them remained uncontrolled, and almost 40 % of low-risk patients received medications unreasonably [27]. Interestingly, in another study, multifaceted comprehensive implementation of a hypertension guideline did not exert an impact on general practitioners’ prescribing of antihypertensive drugs for drug-treated patients with hypertension, even though the participating general practitioners rated themselves as highly motivated to treat according to the guidelines [28]. Table 3 summarizes the observations of above quoted studies. It can be noted that physicians seemed to be well-aware of clinical trials on compliance with hypertension treatment, which showed the compliance rates were good with monotherapy, average with two separate drugs (pills), poor when more than two pills were used and hence switched over from monotherapy to single pill FDC. This strategy will offset the side-effects of maximum dose of one class of drug, simultaneously attracting the synergistic effects of different classes of drugs at low doses. The other advantages of single pill FDC being low cost compared to multiple pills of different classes of drugs apart from better compliance.
Table 3

Observations from different studies highlighting antihypertensive drug utilization and adherence

Author NameNumber of subjects involvedObservation/Remarks
Xavier et al. [20]380 patientsSmall doses of different classes of antihypertensive drug are more beneficial than a high dose of one
Shipra et al. [21]22 prescription pattern monitoring studiesAntihypertensive utilization pattern is in accordance with the international guidelines different antihypertensive drug combinations in practice has a positive impact on the overall BP control
Murphy et al. [22]51 studiesNo significant differences in urban versus rural settings
Odili et al. [23]501 case notesFair compliance with stated guidelines
Ahmad et al. [24]13 doctors for 320 hypertensive patientsDoctors poorly adhered to Malaysian Clinical Practice Guideline (CPG)-2008 in hypertensive patients with diabetes and LVH. A better hypertension control was seen with ACEIs and guidelines-adherent therapy
Abdulameer et al. [25]303 Cardiac complicated hypertension85.30 % adherence to guidelines
Observations from different studies highlighting antihypertensive drug utilization and adherence

Cost implications in antihypertensive drugs Use

The cost of medications has always been a barrier to an effective treatment. The increasing prevalence of hypertension and the continually increasing expense of its treatment influence the prescribing patterns among physicians and compliance to the treatment by the patients. In developing countries like India, unlike developed countries, patients are not covered by insurance schemes and are paying out of their pockets for their healthcare. Therefore, they would benefit if physicians provide better services based on rational and cost-effective drug prescription [29]. According to a cost analysis study by Rachana et al., alpha-blockers were the highest ranked in terms of cost utilized per year followed by ACEIs, ARBs, CCBs, BBs and diuretics in the same order. Thus they found diuretics to be the most cost-effective antihypertensive to be prescribed [30]. Similarly, Amira et al. observed that diuretics were the most cost-effective drugs for hypertension [31]. Additionally, the cost of drugs varied based on the type of hospitals, whether government or private, according to a study by Rimoy et al., the costs of nifedipine, bendrofluazide and frusemide were about five to six times higher in private hospitals than at the government-owned pharmacies [8]. Noteworthy is that adherence to guidelines while prescribing antihypertensive drugs results in substantial savings in prescription costs [32]. The presence of comorbidities further adds to the problem of increased economic burden. Osibogun and Okwor demonstrated a statistically significant association between co-morbid conditions and higher prescription costs with 73.7 % and 63.2 % of those with diabetes and renal disease respectively having prescription costs in the high cost group (p < 0.05) [33]. The cost implication findings from the above studies are summarized in Table 4.
Table 4

Cost implication findings from various studies

Author NameNumber of subjects involvedMono-/combination therapy prescribedObservation/Remarks
Rachana et al. [30]300 prescriptionsMono (48.94 %), CCBCostliest - Alpha-blocker
Cost effective - Diuretic
Amira and Okubadejo [31]225 black patientsCCBCost effective - Amiloride
Rimoy [8]600 patientsDiureticsGovt. shops drugs 5–6 times cheaper than private shops
Fisher and Avorn [32]133,624 patientsCombination (CCB + ACEI)Adherence to guidelines result in savings
Osibogun and Okwor [33]147 prescriptionsDiuretics 79.6 %Co-morbid conditions had high cost prescriptions
Cost implication findings from various studies

Use of antihypertensives in special population

The management of hypertension needs special attention in patient population such as, elderly, pediatrics, pregnant women, and hypertension associated with co-morbidities. Often it qualifies for combination therapy to achieve target BP levels. There are several studies, which evaluated the prescription pattern of antihypertensive drugs in such patient population. In a prospective, observational study conducted on geriatric antihypertensive patients, it was noted that the most common drug classes prescribed were CCBs (37 %) and ACEIs (21 %), and amlodipine was the most commonly prescribed drug (37 %). The most common anti-hypertensive FDC prescribed was telmisartan + hydrochlorothiazide (15 %) and most common two drug combination therapy was amlodipine + atenolol (7 %) [34]. In another study by Fadare et al., antihypertensive drugs accounted for 30.6 % of the total prescriptions of 220 elderly patients. The authors opined that physicians should be specifically trained regarding prescribing to the geriatric population [35]. An observational and cross-sectional prospective prescription audit study was carried-out to evaluate antihypertensive drug prescription patterns, rationality and adherence to JNC 7 guidelines in postmenopausal women. It was noted that ARBs were frequently prescribed as monotherapy and 31.6 % of patients were on a two-drug combination. Majority of the prescriptions showed non-adherence as per recommendations for pre-hypertension. The study concluded that except polypharmacy, antihypertensive prescription trends largely adhere to existing guidelines and are rational [36]. Though there is a scarcity of sufficient data in Indian context, some authors have evaluated antihypertensive medication use in hypertensive diabetes mellitus patients. In a cross-sectional study, Dhanaraj et al. observed that ACEIs were most commonly prescribed antihypertensives (59 %) and most of the patients (55 %) were on multiple drug therapy. In this study, although prescribing pattern of antihypertensives was in accordance with guidelines, there still remained a significant number of patients with uncontrolled hypertension [37]. In a similar patient population, Janagan et al. observed that most of the patients received more than one antihypertensive (75.2 %), with a combination of ACEIs and thiazide diuretics being the most common. This pattern was compliant with JNC7 guidelines [38] Hussain et al. conducted a retrospective, randomized, non-interventional study in 117 subjects to evaluate patterns of drug therapy among diabetic hypertensive patients with other complications. It was found that the most common drug administered for diabetes was metformin, whereas for hypertension, it was telmisartan. There was a positive relationship between fasting blood glucose and systolic blood pressure. The notable gap in the present prescribing pattern was found to be underutilization of diuretics [39]. Adolescent hypertensives seem to be undertreated, with only 23 % of them receiving antihypertensive prescription, according to a study by Yoon et al. Further, ACEIs were the most frequently prescribed monotherapy [40]. In a study by St. Peter et al. on hypertensive subjects on dialysis, the prescription patterns varied by dialysis modality in the initial six months. Further, it was observed that majority of patients who were on BBs, drugs inhibiting the renin angiotensin system, and dihydropyridine CCBs at 6 months of dialysis did not take prescriptions for these drugs by month 24. Additionally, the specific drugs prescribed varied based on factors like race/ethnicity, age and presence of comorbidities [41] The key observations of the studies discussed are summarized in Table 5.
Table 5

Observations of antihypertensives use in special population from various studies

Author NameNumber of Subjects InvolvedObservation/Remarks
Altaf et al. [34]100 geriatric patientsThe drug class most commonly prescribed was CCBs and the anti-hypertensive drug combinations were considerable, and this practice impacted positively on the overall BP control.
Fadare et al. [35]220 elderly patientsAntihypertensives accounted for 30.6 % prescriptions
Tondon et al. [36]500 prescriptions to PMWAdherence rates to JNC-7 were adequate in Stage 1, hypertensive emergency and urgency. It was inadequate in pre-hypertension and Stage 2 hypertension.
Dhanaraj et al. [37]1186 hypertensive patients with type 2 DM patientsAdhered to guidelines
Janagan et al. [38]85 hypertensive patients with type 2 DMPrescription pattern was in accordance with the JNC 7 recommended treatment of hypertension with type 2 DM
Hussain et al. [39]117 hypertensive patients with type 2 DMMost common drug used was telmisartan. A positive relationship between fasting blood glucose and SBP observed. Underutilization of diuretics was noted.
Yoon et al. [40]4296 adolescent hypertensivesOnly 23 % received antihypertensive prescription
St. Peter et al. [41]13072 adult patients on dialysisConsiderable proportions of patients with prescriptions for BBs, renin angiotensin system agents, and dihydropyridine CCBs in month 6 no longer had prescriptions for these medications by month 24.
Observations of antihypertensives use in special population from various studies

Conclusion

The continued challenges in the management of hypertension still need special attention. A number of national and international guidelines for the management of hypertension have been published highlighting mono- or combination therapy according to the BP levels and associated comorbidity. Worldwide, hypertension treatment strategies have varied widely over time in terms of initial drug of choice from diuretic to ACEI/ ARB/ CCB, from monotherapy to low dose combination single pill therapy. National health policy makers should consider evaluation and treatment of hypertension as a right in public health system for better outcomes in terms of morbidity and mortality from hypertension. The evaluation pattern, patient adherence to the treatment, physician adherence to hypertension management guidelines, cost implications and other data concerning comorbid conditions have been explored in many clinical studies. Inspite of these data and published guidelines, inconsistencies exist towards treatment approach, because of which physicians sometimes have to individualize the therapy, based on specific patient characteristics and response to treatment. In developing countries like India, more systematic studies are required on the evaluation of prescribing patterns and guideline-based antihypertensive medications’ use, which can be tailored to suit the patients' requirements.
  27 in total

1.  Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement.

Authors:  John M Flack; Domenic A Sica; George Bakris; Angela L Brown; Keith C Ferdinand; Richard H Grimm; W Dallas Hall; Wendell E Jones; David S Kountz; Janice P Lea; Samar Nasser; Shawna D Nesbitt; Elijah Saunders; Margaret Scisney-Matlock; Kenneth A Jamerson
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  Improvement of blood pressure control in a hypertension clinic: a 10-year follow-up study.

Authors:  Y Ohta; T Tsuchihashi; K Fujii; K Matsumura; Y Ohya; K Uezono; I Abe; M Iida
Journal:  J Hum Hypertens       Date:  2004-04       Impact factor: 3.012

3.  Standards of medical care in diabetes--2013.

Authors: 
Journal:  Diabetes Care       Date:  2013-01       Impact factor: 19.112

4.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Stephen S Lim; Theo Vos; Abraham D Flaxman; Goodarz Danaei; Kenji Shibuya; Heather Adair-Rohani; Markus Amann; H Ross Anderson; Kathryn G Andrews; Martin Aryee; Charles Atkinson; Loraine J Bacchus; Adil N Bahalim; Kalpana Balakrishnan; John Balmes; Suzanne Barker-Collo; Amanda Baxter; Michelle L Bell; Jed D Blore; Fiona Blyth; Carissa Bonner; Guilherme Borges; Rupert Bourne; Michel Boussinesq; Michael Brauer; Peter Brooks; Nigel G Bruce; Bert Brunekreef; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Fiona Bull; Richard T Burnett; Tim E Byers; Bianca Calabria; Jonathan Carapetis; Emily Carnahan; Zoe Chafe; Fiona Charlson; Honglei Chen; Jian Shen Chen; Andrew Tai-Ann Cheng; Jennifer Christine Child; Aaron Cohen; K Ellicott Colson; Benjamin C Cowie; Sarah Darby; Susan Darling; Adrian Davis; Louisa Degenhardt; Frank Dentener; Don C Des Jarlais; Karen Devries; Mukesh Dherani; Eric L Ding; E Ray Dorsey; Tim Driscoll; Karen Edmond; Suad Eltahir Ali; Rebecca E Engell; Patricia J Erwin; Saman Fahimi; Gail Falder; Farshad Farzadfar; Alize Ferrari; Mariel M Finucane; Seth Flaxman; Francis Gerry R Fowkes; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Santu Ghosh; Edward Giovannucci; Gerhard Gmel; Kathryn Graham; Rebecca Grainger; Bridget Grant; David Gunnell; Hialy R Gutierrez; Wayne Hall; Hans W Hoek; Anthony Hogan; H Dean Hosgood; Damian Hoy; Howard Hu; Bryan J Hubbell; Sally J Hutchings; Sydney E Ibeanusi; Gemma L Jacklyn; Rashmi Jasrasaria; Jost B Jonas; Haidong Kan; John A Kanis; Nicholas Kassebaum; Norito Kawakami; Young-Ho Khang; Shahab Khatibzadeh; Jon-Paul Khoo; Cindy Kok; Francine Laden; Ratilal Lalloo; Qing Lan; Tim Lathlean; Janet L Leasher; James Leigh; Yang Li; John Kent Lin; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Joelle Mak; Reza Malekzadeh; Leslie Mallinger; Wagner Marcenes; Lyn March; Robin Marks; Randall Martin; Paul McGale; John McGrath; Sumi Mehta; George A Mensah; Tony R Merriman; Renata Micha; Catherine Michaud; Vinod Mishra; Khayriyyah Mohd Hanafiah; Ali A Mokdad; Lidia Morawska; Dariush Mozaffarian; Tasha Murphy; Mohsen Naghavi; Bruce Neal; Paul K Nelson; Joan Miquel Nolla; Rosana Norman; Casey Olives; Saad B Omer; Jessica Orchard; Richard Osborne; Bart Ostro; Andrew Page; Kiran D Pandey; Charles D H Parry; Erin Passmore; Jayadeep Patra; Neil Pearce; Pamela M Pelizzari; Max Petzold; Michael R Phillips; Dan Pope; C Arden Pope; John Powles; Mayuree Rao; Homie Razavi; Eva A Rehfuess; Jürgen T Rehm; Beate Ritz; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Jose A Rodriguez-Portales; Isabelle Romieu; Robin Room; Lisa C Rosenfeld; Ananya Roy; Lesley Rushton; Joshua A Salomon; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; Amir Sapkota; Soraya Seedat; Peilin Shi; Kevin Shield; Rupak Shivakoti; Gitanjali M Singh; David A Sleet; Emma Smith; Kirk R Smith; Nicolas J C Stapelberg; Kyle Steenland; Heidi Stöckl; Lars Jacob Stovner; Kurt Straif; Lahn Straney; George D Thurston; Jimmy H Tran; Rita Van Dingenen; Aaron van Donkelaar; J Lennert Veerman; Lakshmi Vijayakumar; Robert Weintraub; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Warwick Williams; Nicholas Wilson; Anthony D Woolf; Paul Yip; Jan M Zielinski; Alan D Lopez; Christopher J L Murray; Majid Ezzati; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

5.  Blood pressure control and pharmacotherapy patterns in the United States before and after the release of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) guidelines.

Authors:  James H Jackson; John Sobolski; Russ Krienke; Ken S Wong; Feride Frech-Tamas; Brian Nightengale
Journal:  J Am Board Fam Med       Date:  2008 Nov-Dec       Impact factor: 2.657

6.  Physician adherence to hypertension treatment guidelines and drug acquisition costs of antihypertensive drugs at the cardiac clinic: a pilot study.

Authors:  Shaymaa Abdalwahed Abdulameer; Mohanad Naji Sahib; Noorizan Abd Aziz; Yahaya Hassan; Hadeer Akram Abdul Alrazzaq; Omar Ismail
Journal:  Patient Prefer Adherence       Date:  2012-01-31       Impact factor: 2.711

Review 7.  A systematic review of prescription pattern monitoring studies and their effectiveness in promoting rational use of medicines.

Authors:  Shipra Jain; Prerna Upadhyaya; Jaswant Goyal; Abhijit Kumar; Pushpawati Jain; Vikas Seth; Vijay V Moghe
Journal:  Perspect Clin Res       Date:  2015 Apr-Jun

8.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

9.  Prescription pattern and prevalence of potentially inappropriate medications among elderly patients in a Nigerian rural tertiary hospital.

Authors:  Joseph O Fadare; Segun Matthew Agboola; Olumide Augustine Opeke; Rachel A Alabi
Journal:  Ther Clin Risk Manag       Date:  2013-03-13       Impact factor: 2.423

10.  Antihypertensive drug prescription patterns, rationality, and adherence to Joint National Committee-7 hypertension treatment guidelines among Indian postmenopausal women.

Authors:  Vishal R Tandon; Sudhaa Sharma; Shagun Mahajan; Annil Mahajan; Vijay Khajuria; Vivek Mahajan; Chander Prakash
Journal:  J Midlife Health       Date:  2014-04
View more
  30 in total

1.  The Plethora of Angiotensin-Converting Enzyme-Processed Peptides in Mouse Plasma.

Authors:  Margarita Semis; Gabriel B Gugiu; Ellen A Bernstein; Kenneth E Bernstein; Markus Kalkum
Journal:  Anal Chem       Date:  2019-05-07       Impact factor: 6.986

2.  Combination Antihypertensive Therapy Prescribing and Blood Pressure Control in a Real-World Setting.

Authors:  Oyunbileg Magvanjav; Rhonda M Cooper-Dehoff; Caitrin W McDonough; Yan Gong; William R Hogan; Julie A Johnson
Journal:  Am J Hypertens       Date:  2020-04-01       Impact factor: 2.689

3.  History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium.

Authors:  Albina N Minlikeeva; Jo L Freudenheim; Rikki A Cannioto; J Brian Szender; Kevin H Eng; Francesmary Modugno; Roberta B Ness; Michael J LaMonte; Grace Friel; Brahm H Segal; Kunle Odunsi; Paul Mayor; Emese Zsiros; Barbara Schmalfeldt; Rüdiger Klapdor; Thilo Dӧrk; Peter Hillemanns; Linda E Kelemen; Martin Kӧbel; Helen Steed; Anna de Fazio; Susan J Jordan; Christina M Nagle; Harvey A Risch; Mary Anne Rossing; Jennifer A Doherty; Marc T Goodman; Robert Edwards; Keitaro Matsuo; Mika Mizuno; Beth Y Karlan; Susanne K Kjær; Estrid Høgdall; Allan Jensen; Joellen M Schildkraut; Kathryn L Terry; Daniel W Cramer; Elisa V Bandera; Lisa E Paddock; Lambertus A Kiemeney; Leon F Massuger; Jolanta Kupryjanczyk; Andrew Berchuck; Jenny Chang-Claude; Brenda Diergaarde; Penelope M Webb; Kirsten B Moysich
Journal:  Cancer Causes Control       Date:  2017-03-14       Impact factor: 2.506

4.  Rates of appropriate laxative prophylaxis for opioid-induced constipation in veterans with lung cancer: a retrospective cohort study.

Authors:  Timothy J Brown; Neil Keshvani; Arjun Gupta; Hui Yang; Deepak Agrawal; Tri C Le; David E Gerber; Carlos A Alvarez
Journal:  Support Care Cancer       Date:  2020-03-02       Impact factor: 3.603

Review 5.  A practical approach to the pharmacological management of hypertension in older people.

Authors:  Nikesh Parekh; Amy Page; Khalid Ali; Kevin Davies; Chakravarthi Rajkumar
Journal:  Ther Adv Drug Saf       Date:  2016-12-27

6.  Antihypertensive Prescription Pattern and Compliance to JNC 7 and JNC 8 at Tertiary Care Government Hospital, Hyderabad, India: A Cross-sectional Retrospective Study.

Authors:  Varsha Varakantham; Ashok Kumar Kurakula Sailoo; Dinesh Kumar Bharatraj
Journal:  Hosp Pharm       Date:  2017-11-01

7.  Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005-2016.

Authors:  Catherine G Derington; Jordan B King; Jennifer S Herrick; Daichi Shimbo; Ian M Kronish; Joseph J Saseen; Paul Muntner; Andrew E Moran; Adam P Bress
Journal:  Hypertension       Date:  2020-03-09       Impact factor: 10.190

8.  Pharmacokinetics, Safety and Tolerability of Tylerdipine Hydrochloride, a Novel Dihydropyridine Dual L/T-type Calcium Channel Blocker, after Single and Multiple Oral Doses in Healthy Chinese Subjects.

Authors:  Sufeng Zhou; Yuanyuan Wang; Lu Wang; Lijun Xie; Juan Chen; Yun Liu; Hongwen Zhang; Yuqing Zhao; Ning Ou; Feng Shao
Journal:  Clin Drug Investig       Date:  2019-01       Impact factor: 2.859

9.  Challenges experienced by patients with hypertension in Ghana: A qualitative inquiry.

Authors:  Fidelis Atibila; Gill Ten Hoor; Emmanuel Timmy Donkoh; Gerjo Kok
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

10.  The Ecology of Antihypertensives in the United States, 1997-2017.

Authors:  Michael E Johansen; Joshua D Niforatos; Jeremey B Sussman
Journal:  J Gen Intern Med       Date:  2020-09-23       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.